European Companies Search Engine

Quick Search Power Search
Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

Forschungsinstitut für molekulare Pathologie GmbH, Vienna, Austria

Watch

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Dossier

The dossier is a printable PDF file, summarizing information and publications for this company. The creation of dossiers is included in your subscription. After the creation of the dossier is completed, it will be sent to your email address .

Add to dossier (if available):

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Name

Forschungsinstitut für molekulare Pathologie GmbH

Register

Fb
Firmenbuch 082531w
Lei
529900XIA762B58MYP48

Address

Campus-Vienna-Biocenter 1 Viehmarktgasse 2B, 1030 Wien, Austria

Financials

History

Marketing & Tech

Network

Loading network
CSV export

Quarterly Exports in CSV

Now available in CSV format and optimized for applications in AI and Analytics:
North Data's quarterly exports have become the industry standard for company information.

Publications

16 Feb 2024 via Boehringer Ingelheim International GmbH, also 13/03/2023, 12/01/2022, 13/01/2021, 13/02/2020, 23/01/2019, 01/02/2018, 09/01/2017, 02/12/2015, 10/01/2011
Shareholder: Boehringer Ingelheim International GmbH
12 Sept 2023
Annual report for the year ending 31/12/2022
1 Jun 2023 in Sat
State Aid (€1,770,731): FFG Industry Guideline, 2022
1 Mar 2023 in Fts
EU funding (€270,330): 101073238 - Regenerate-IT - Learning From Animals HOW to Regenerate: Multidisciplinary Training Programme in Regenerative Biology
14 Feb 2023
Officer: Tanja Winkler · No longer Officer: Meinrad Busslinger · Capital: €36,336
1 Jan 2023 in Fts
EU funding (€270,332): 101072505 - Cohesinet - Cohesin and ITS Regulators: From Chromosome Dynamics and Nuclear Architecture to Human Diseases
1 Jan 2023 in Fts
EU funding (€2,000,000): 101044495 - Game - Mechanism of Vertebrate Sperm-EGG Recognition and Fusion
21 Dec 2022 via C.H. Boehringer Sohn AG & Co. KG, also 22/12/2021, 15/12/2020, 08/01/2020, 08/01/2020, 13/12/2018, 03/01/2018, 12/01/2017, 25/02/2016, 17/04/2015, 14/05/2014, 14/02/2013, 16/12/2011, 21/12/2010, 22/12/2009, 11/12/2008, 19/02/2008
Shareholder: C.H. Boehringer Sohn AG & Co. KG
13 Sept 2022
Annual report for the year ending 31/12/2021
Year 2022 in Fts
6 EU fundings (total €1,044,835): 101015478 - Axomatrx - HOW do Dynamic Changes Extracellular Matrix Guide Regenerative Events in Axolotl? …
Year 2021 in Fts
6 EU fundings (total €2,490,175): 890218 - Riboheterogeneity - Functional Analysis of Ribosome Heterogeneity During Zebrafish Embryogenesis …
23 Nov 2021
Annual report for the year ending 31/12/2020
Year 2021 in Hor
8 EU fundings (€174,167): Mechanism, regulation and functions of genome folding through loop extrusion by cohesin-NIPBL …
Year 2020 in Fts
7 EU fundings (total €9,197,792): 949081 - Rnapaxport - Mechanisms of Human Mrna Packaging and Export …
Year 2020 in Hor
5 EU fundings (€1,500,000): Mechanisms of human mRNA packaging and export …
28 Oct 2020
Annual report for the year ending 31/12/2019
10 Feb 2020 in Sat
State Aid (€3,000,000): promotion of applied research, development and innovation on the basis of the Austrian Research Promotion Agency (mbH)
Year 2019 in Hor
7 EU fundings (€150,000): High-throughput 4D imaging for nanoscale cellular studies …
Year 2019 in Fts
6 EU fundings (total €2,689,201): 819336 - Neuromag - the Neurological Basis of the Magnetic Sense …
5 Sept 2019
Annual report for the year ending 31/12/2018
15 Nov 2018
Annual report for the year ending 31/12/2017
6 Jun 2018 in Hor
EU funding (€166,157): Investigating the pathogenic mechanisms underlying TUBB2B-related brain malformations using induced pluripotent stem cells and cerebral organoids.
30 May 2018 in Hor
EU funding (€27,693): Sleep homeostasis in Caenorhabditis elegans
Year 2018 in Fts
5 EU fundings (total €6,325,659): 759590 - Combatcancer - Rational Combination Therapies for Metastatic Cancer …
24 Jan 2018 in Hor
EU funding (€1,500,000): Rational combination therapies for metastatic cancer
20 Dec 2017
No longer Shareholder (1) · Shareholder: Boehringer Ingelheim International GmbH, Ingelheim/Rhein, Deutschland (HRB 21063 Amtsgericht Mainz) · Capital: €36,336
16 Nov 2017
Annual report for the year ending 31/12/2016 (only announcement) · Capital: €36,336
10 Aug 2017 in Hor
EU funding (€2,500,000): Transcriptional control of plasma cell development and function
22 May 2017 in Hor
EU funding (€2,325,659): Understanding the evolution of regeneration-permissive gene expression and positional memory in Axolotl limb regeneration
18 Nov 2016
Address · Capital: €36,336
1 Nov 2016
Address · Capital: €36,336
19 Oct 2016
Annual report for the year ending 31/12/2015 (only announcement) · Capital: €36,336
1 Oct 2016 in Fts
EU funding (€2,499,299): 694978 - Parg_DEG_Signal - NO Stress with Parg: Mechanisms of a Distinct Phospho-Mark to Coordinate Stress Response and Protein Quality Control
1 Oct 2016 in Fts
EU funding (€2,500,000): 693949 - Cohesinmolmech - Molecular Mechanisms of Cohesin-Mediated Sister Chromatid Cohesion and Chromatin Organization
Year 2016 in Hor
4 EU fundings (€166,157): Molecular mechanisms of cohesin-mediated sister chromatid cohesion and chromatin organization …
1 Mar 2016 in Fts
EU funding (€124,710): 704698 - Widebrainimaging - Development of High-Speed Microscopes to Study Wide-Scale Neural Activity
3 Oct 2015
Annual report for the year ending 31/12/2014 (only announcement) · Capital: €36,336
1 Sept 2015 in Fts
EU funding (€1,999,906): 647320 - Enhancer ID - Identification and Functional Characterization of Mammalian Enhancers and Transcriptional CO-Factors During Cellular Signaling and Cell Fate Transitions
2 Jun 2015 in Hor
EU funding (€1,999,906): Identification and functional characterization of mammalian enhancers and transcriptional co-factors during cellular signaling and cell fate transitions
15 Feb 2015 in Fts
EU funding (€186,784): An in-Vivo Rnai Approach to Identify and Evaluate Suppressors of Anti-Tumor T Cell Immunity
5 Aug 2014
Annual report for the year ending 31/12/2013 (only announcement) · Capital: €36,336
Year 2014 in Fts
6 EU fundings (total €4,918,065): The Cellular and Molecular Basis of Magnetoreception …
5 Sept 2013
Annual report for the year ending 31/12/2012 (only announcement) · Capital: €36,336
Year 2013 in Fts
4 EU fundings (total €1,873,315): Systemic Analysis of Chromatin-Regulatory Genes in Pdac Using Advanced in Vivo Rnai …
6 Mar 2013
Managing Director (1) · No longer Managing Director (1) · No longer Officer (1) · Capital: €36,336
20 Sept 2012
Annual report for the year ending 31/12/2011 (only announcement) · Capital: €36,336
Year 2012 in Fts
4 EU fundings (total €5,669,064): Transcriptional Networks Controlling Lymphocyte Development …
9 Sept 2011
Annual report for the year ending 31/12/2010 (only announcement) · Capital: €36,336
1 Feb 2011 in Fts
EU funding (€349,045): 262067 - Prime-XS - FP7 Infra2010
12 Oct 2010
Annual report for the year ending 31/12/2009 (only announcement) · Capital: €36,336
Year 2010 in Fts
6 EU fundings (total €4,225,990): Mitosys …
9 Sept 2009
Annual report for the year ending 31/12/2008 (only announcement) · Capital: €36,336
Year 2009 in Fts
4 EU fundings (total €2,765,211): Meiosys …
30 Oct 2008
Annual report for the year ending 31/12/2007 (only announcement) · Capital: €36,336
1 Oct 2008 in Fts
EU funding (€714,850): KinetoCore
1 Oct 2008 in Fts
EU funding (€185,136): KinetoCore
1 Jul 2008
No longer Officer (1) · Capital: €36,336
7 Mar 2008
Officer (1) · Capital: €36,336
1 Mar 2008 in Fts
EU funding (€155,259): PAX5Targets
10 Jul 2007
Annual report for the year ending 31/12/2006 (only announcement) · Capital: €36,336
3 Jun 2006
Annual report for the year ending 31/12/2005 (only announcement) · Capital: €36,336
10 Feb 2006
Managing Director (1) · No longer Managing Director (1) · Capital: €36,336
14 Sept 2005
Annual report for the year ending 31/12/2004 (only announcement) · Capital: €36,336
9 Feb 2005
Managing Director: Harald Isemann · No longer Officer (2) · No longer Managing Director (1) · Capital: €36,336
10 Sept 2004
No longer Officer (1) · Capital: €36,336
7 Aug 2004
Annual report for the year ending 31/12/2003 (only announcement) · Capital: €36,336
14 Apr 2004
Officer: Harald Isemann · Capital: €36,336
28 Oct 2003
Annual report for the year ending 31/12/2002 (only announcement) · Capital: €36,336
28 Dec 2002
Managing Director (1) · No longer Managing Director (1) · Capital: €36,336
15 Aug 2002
Annual report for the year ending 31/12/2001 (only announcement) · Capital: €36,336
26 Apr 2002
Shareholder (1) · Shareholder: Boehringer Ingelheim International GmbH, Ingelheim/Rhein, Deutschland (HRB 1063 Amtsgericht Bingen) · Capital: €36,336
18 Dec 2001
Shareholder (1) · No longer Shareholder (1) · Capital: 500,000 ATS
22 Nov 2001
Annual report for the year ending 31/12/2000 (only announcement) · Capital: 500,000 ATS
22 Sept 2000
Annual report for the year ending 31/12/1999 (only announcement) · Capital: 500,000 ATS
10 Sept 1999
Annual report for the year ending 31/12/1998 (only announcement) · Capital: 500,000 ATS
30 Dec 1998
Annual report for the year ending 31/12/1997 (only announcement) · Capital: 500,000 ATS
2 Sept 1998
Managing Director (1) · No longer Managing Director (1) · Capital: 500,000 ATS
13 Aug 1997
Officer (1) · Capital: 500,000 ATS
15 Jan 1997
Managing Director (2) · No longer Managing Director (1) · Capital: 500,000 ATS
12 May 1994
Shareholder (1) · Shareholder: Boehringer Ingelheim International GmbH, Ingelheim/Rhein, Deutschland · No longer Shareholder: Genentech Inc., San Franciso, USA · Capital: 500,000 ATS
4 Mar 1994
Reg­is­tra­tion · PPA (3) · MD (1) · SH: Boehringer Ingelheim International GmbH, Ingelheim/Rhein, Deutschland, Genentech Inc., San Franciso, USA · Address · Deadline for annual balance: 31.12. …

Mentions

12 Sept 2023
Direct parent: C.H. Boehringer Sohn AG & Co. KG
12 Sept 2023
Ultimate parent: C.H. Boehringer Sohn AG & Co. KG

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Creative Commons License The visualizations for "Forschungsinstitut für molekulare Pathologie GmbH, Vienna, Austria" are provided by North Data and may be reused under the terms of the Creative Commons CC-BY license.

Printing is only available to North Data premium service subscribers.
Close